CytoDel® Inc. was founded in 2012 to commercialize technology developed by its founders at the NYU-Grossman School of Medicine (NYU). The Company’s patented and proprietary technology platform is based on producing recombinant derivatives of botulinum neurotoxin (BoNT) engineered to create high value products with customized properties, and to deliver active agents to therapeutic targets inside neurons. BoNT is best known as the active ingredient in pharmaceutical products such as Botox® (Allergan).

CytoDel was founded to address limitations of the available countermeasures to weaponized BoNT, a Tier 1 biodefense threat. Engineered BoNT derivatives can be used as a “Trojan horse” to deliver therapeutic antibodies to the inside of neurons, enabling development of the first BoNT antidote that targets the toxin after it has been internalized into neurons, where standard antibodies cannot go. An accelerated regulatory pathway is available for Cyto-111, CytoDel’s lead biodefense product via the Animal Rule. This is a non-traditional route to approval that only requires Phase 1 Safety trials, plus two pivotal animal studies. CytoDel is also pursuing synergistic development programs, all based on the recombinant BoNT platform. For the BoNT pharmaceutical market, CytoDel's technology allows for the manipulation of BoNT at the molecular level, to create engineered “Botox-like” products with tailored properties such as an improved therapeutic window and longer duration of action.

For more information on our science click on the TECHNOLOGY tab above.